1-15 of 107
The Hidden Respiratory Burden of Obesity: Understanding the Clinical Consequences
Clinician's RoundtableThe Hidden Respiratory Burden of Obesity: Understanding the Clinical Consequences
Understanding the Growing Impacts of Obesity on Patient Outcomes and Care Delivery
Clinician's RoundtableUnderstanding the Growing Impacts of Obesity on Patient Outcomes and Care Delivery
MASLD Explained: A Modern Framework for a Multisystem Condition
Clinician's RoundtableMASLD Explained: A Modern Framework for a Multisystem Condition
Unveiling the Role of Obesity in MASLD Progression
Clinician's RoundtableUnveiling the Role of Obesity in MASLD Progression
New Insights into VKD: Exploring Maternal Obesity and Neonatal Vitamin K Status
Clinician's RoundtableNew Insights into VKD: Exploring Maternal Obesity and Neonatal Vitamin K Status
From Gut Microbe to Metabolic Modulator: The Potential Role of R. hominis in Obesity
Clinician's RoundtableFrom Gut Microbe to Metabolic Modulator: The Potential Role of R. hominis in Obesity
- advertisement
Understanding Thyroid Hormone Dynamics After COVID-19 Infection
Clinician's RoundtableUnderstanding Thyroid Hormone Dynamics After COVID-19 Infection
Albuminuria: An Overlooked Red Flag in Cardiovascular Risk
Conversations in CV Risk AssessmentAlbuminuria: An Overlooked Red Flag in Cardiovascular Risk
Uncovering Cardiovascular Risk in Patients with Target Blood Pressure
Conversations in CV Risk AssessmentUncovering Cardiovascular Risk in Patients with Target Blood Pressure
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Heart MattersRethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
NephrologyFinerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
NephrologyImplications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
- advertisement
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
NephrologyNew Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
NephrologyThe Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Pediatric Psoriasis in Focus: Emerging Insights on Immune and Obesity Drivers
On the Frontlines of PsoriasisPediatric Psoriasis in Focus: Emerging Insights on Immune and Obesity Drivers
